Development

Feliza Mirasol is the science editor for 

Articles

Current and newer biologic modalities pose increasingly complex challenges to the detection and characterization of protein aggregates.

Risky Business: Assessing Protein Aggregation Grows Increasingly Challenging

Agnes Shanley is senior editor of Pharmaceutical Technology.

Manufacturers and the US government are investing heavily in traditional and non-traditional forms and materials to ensure supplies of containers and delivery devices for COVID-19 treatments and vaccines. 


COVID-19: Shoring Up the Drug Delivery Infrastructure

Cynthia A. Challener, PhD, is a contributing editor to BioPharm International.

RNA is easier to manipulate than DNA but challenging to deliver to the right cells.

Can Using RNA Simplify Gene Therapy Development?

With the acquisition, Orgenesis will combine TamirBio’s ranpirnase antiviral platform with its Bioxome technology.

Orgenesis to Acquire Tamir Biotechnology for Broad Spectrum Antiviral Platform

Biopharma companies responding to the COVID-19 outbreak think accelerating the development of vaccines is safe.

Can Vaccine Development Be Safely Accelerated?

As a result of the rising use and development of biological drugs, the biopharma industry is witnessing an increase in the adoption of prefilled syringes.

On Point: Biologics Drive Growth in Pre-Filled Syringes

Contract service organizations can offer biopharma companies early insight into dangers that may hinder a drug’s later development.

Seeking Early Answers to Formulation Questions

CHMP has recommended that Ervebo (rVSVΔG-ZEBOV-GP), a vaccine for active immunization against Ebola, be granted conditional marketing authorization in the EU.

First Ebola Vaccine Gains Conditional Marketing Authorization Recommendation

On Tuesday, Nov. 5, 2019, Karima Yadi from Becton Dickinson & Co. will present the challenges of using, and necessity for, shorter needles and integrated systems with high viscosity drugs, such as biologics, to improve the patient experience at CPhI Worldwide.

Improving the Patient Experience with High Viscosity/High Volume Drugs

Leveraging automation and a step-by-step approach are keys to success.

Formulation and Drug Delivery, Biologic Drugs